Copy
View this email in your browser

Lancet Commission on Essential Medicines Policies

 

Welcome to the June 2016 newsletter of the Lancet Commission on Essential Medicines Policies


This is the current issue of the Lancet Commission on Essential Medicines Policies Newsletter. Please check our website for more details on our work: http://www.bu.edu/lancet-commission-essential-medicines-policies/
 
Recent Updates: 

Ten years UNITAID
This year UNITAID celebrates its 10 year anniversary. Over the last decade it has promote availability of affordable medicines and technologies for the treatment of HIV, malaria and TB in low- and middle-income countries.

About 60% of its funding comes from taxes on airline ticket levies in ten countries. Making essential medicines affordable is one of the five focus areas of The Lancet Commission on EMP report. 
 


World Health Assembly Resolutions related to medicines
In May 2016, two WHA Resolutions were passed that specifically focused on medicines:
  • “Promoting innovation and access to quality, safe, efficacious and affordable medicines for children”
  • “Addressing the global shortage of medicines and vaccines”
Several of the aspects that the resolutions address are part of the ongoing discussion of The Lancet Commission on EMP and feature part in the upcoming report, namely selection of essential medicines for reimbursement, affordability of essential medicines and development of essential medicines for vulnerable populations.
Recent Publications
Upcoming Events and News relevant to Essential Medicines Policies: 
Spotlight: 

Lancet EMP Commissioner: Kees De Joncheere

Email: cpdejoncheere@gmail.com

Kees de Joncheere was the Director of the Essential Medicines and HealthProducts  Department at WHO Headquarters, Geneva until April 2016. Before this he worked for more than 10 years as Regional Advisor for Pharmaceuticals and Health Technologies in the WHO Regional Office for Europe, and more recently as the WHO Representative and Head of Country Office in Kiev, Ukraine. From the Netherlands, his international career began working with the Government of the Netherlands in a health services project in what was then North Yemen. For more than 10 years he served the Pan American Health Organization in Brazil, the Mercosur countries and Central America in the essential medicines area.

Kees de Joncheere holds a Master`s degree in pharmacy, a PharmD and a Master’s degree in business administration from the Universities of Groningen and Amsterdam in the Netherlands, and from National University, San Diego, USA / San José, Costa Rica.

His particular interest is in public policy in the area of medicines, especially pharmaceutical pricing and reimbursement, as well as approaches to strengthening medicines regulation and improving the prescribing and use of medicines. He co-edited the WHO publication Drugs and Money, 7th edition, and is author of several articles and book chapters on pharmaceutical issues.
 
Selected publications of interest:
Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference.
Vogler S, Zimmermann N, Ferrario A, Wirtz VJ, de Joncheere K, Pedersen HB, Dedet G, Paris V, Mantel-Teeuwisse AK, Babar ZU; Scientific Programme Committee of the 2015 PPRI Conference. J Pharm Policy Pract. 2016 Mar 15;9:9.

Tough decisions on essential medicines in 2015. Magrini N, Robertson J, Forte G, Cappello B, Moja LP, de Joncheere K, Kieny MP. Bull World Health Organ. 2015 Apr 1;93(4):283-4. doi: 10.2471/BLT.15.154385. Epub 2015 Mar 12. No abstract available.

Medicines availability for non-communicable diseases: the case for standardized monitoring. Robertson J, Macé C, Forte G, de Joncheere K, Beran D. Global Health. 2015 May 7;11:18. doi: 10.1186/s12992-015-0105-0.

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries.
Leopold C, Mantel-Teeuwisse AK, Vogler S, Valkova S, de Joncheere K, Leufkens HG, Wagner AK, Ross-Degnan D, Laing R. Bull World Health Organ. 2014 Sep 1;92(9):630-640D.

On WHO's essential medicines process and transparency. Magrini N, Robertson J, de Joncheere K, Bero L. BMJ. 2014 Sep 17;349:g5637.
 

Twitter
Website
June, 2016
Copyright © 2016 Lancet Commission on Essential Medicines Policies, All rights reserved.
You are receiving this email because you have expressed interest in the commission, have been involved in the commission process or were recommended by a colleague. You can unsubscribe by clicking the link at the bottom of the email. We encourage you to pass this email along to anyone who might be interested. Please visit our website at http://www.bu.edu/lcemp



unsubscribe from this list    update subscription preferences 

 






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Lancet EMP · 801 Massachusetts Avenue · Boston, MA 02118 · USA

Email Marketing Powered by MailChimp